The Medicines for Human Use (Prescribing by EEA Practitioners) (Amendment) Regulations 2010
S.I. 2010/1673 · Made 23 June 2010
Medicines
Made 23rd June 2010
Laid before Parliament 28th June 2010
Coming into force 26th July 2010
The Secretary of State makes the following Regulations in the exercise of the powers conferred by section 2(2) of the European Communities Act 1972f1. He has been designated for the purpose of section 2(2) of the European Communities Act 1972f2 in relation to medicinal products.
Annotations to the whole text
Footnotes
- f1
-
1972 c.68; section 2(2) was amended by section 27(1)(a) of the Legislative and Regulatory Reform Act 2006 (c.51) and by section 3(3) of and Part 1 of Schedule 1 to the European Union (Amendment) Act 2008 (c.7).
- f2
Contents
- 1Citation, commencement and interpretation
- 2Amendment of regulation 3 of the principal Regulations
- Signature
- Explanatory note
1Citation, commencement and interpretation
These Regulations may be cited as the Medicines for Human Use (Prescribing by EEA Practitioners) (Amendment) Regulations 2010 and shall come into force on 26th July 2010.
In these Regulations “the principal Regulations” means the Medicines for Human Use (Prescribing by EEA Practitioners) Regulations 2008f1.
2Amendment of regulation 3 of the principal Regulations
In regulation 3 of the principal Regulations (prescriptions given by EEA health professionals), in paragraph (2)(c)(iv) omit “, address and the age, if under 12,”.
Signature
Signed by the authority of the Secretary of State for Health.
Earl Howe
Parliamentary Under-Secretary of State,
Department of Health
23rd June 2010
Explanatory note
(This note is not part of the Regulations)
These Regulations amend regulation 3 of the Medicines for Human Use (Prescribing by EEA Practitioners) Regulations 2008 relating to prescriptions provided by doctors and dentists in an EEA State other than the UK or in Switzerland to ensure that there is no longer a requirement for such prescriptions to contain details of the address and the age, if under 12, of the person for whose treatment the prescription is given.
An impact assessment has not been prepared for this instrument as there is no significant impact on the private and voluntary sectors.